Biosotal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biosotal

Property Description
Active ingredient Sotalol hydrochloride
Form Tablet, Intravenous Solution
Pharmacological Class Antiarrhythmic Agent (Class II and Class III)
General Purpose To stabilize and maintain a regular heart rhythm
Origin Synthetic

What is the Active Ingredient and Pharmacological Class of Biosotal?

Biosotal is a prescription-only medication defined by its sole active ingredient, Sotalol hydrochloride. This compound is formally classified as an Antiarrhythmic Agent, a group of drugs designed to manage abnormalities in heart rhythm. Its pharmacological identity is unique due to its dual mechanism of action, which sets it apart from conventional agents: it acts concurrently as a Class II (beta-adrenoreceptor blocking) and a Class III agent in the Vaughan Williams system. This composite profile is a key differentiating feature that allows Sotalol to influence the heart through two critical electrical pathways. Sotalol is a chemically synthetic, single-ingredient substance administered as a racemic mixture, ensuring the delivery of both electrical effects within the single compound.

What Forms Does Sotalol Come In, and What is its General Purpose?

The active compound, Sotalol, is prepared into different dosage forms for patient use, commonly available as oral tablets and as an intravenous solution, dictating the appropriate oral or intravenous routes of administration. This availability is important in scenarios where a rapid intravenous onset is needed followed by long-term oral maintenance. The general purpose of the medication is to promote a stable and regulated heartbeat. It achieves this by simultaneously slowing the heart rate while also prolonging the heart muscle's electrical recovery time. Sotalol is used to regulate episodes of abnormal heart rhythms, helping the heart maintain electrical discipline and supporting circulation.

Regulatory References

  1. NIH DailyMed for Sotalol

What side effects are possible with Biosotal?

Possible Side Effects and Safety Information

The most significant safety concern for Biosotal (Sotalol) is the risk of life-threatening proarrhythmia, primarily Torsade de Pointes (TdP), a form of ventricular tachycardia. This risk is related to the drug's effect of prolonging the QTc interval on the electrocardiogram (ECG) and is dose-dependent, increasing with higher plasma concentrations.

For this reason, therapy must be initiated or re-initiated in a medical facility capable of providing continuous ECG monitoring and cardiac resuscitation. Dosing adjustments are required if the QTc interval exceeds 500 ms.

Common Adverse Reactions

The most frequently reported adverse reactions, consistent with the drug's dual beta-blocking properties, include fatigue, dizziness, bradycardia (slow heart rate), headache, dyspnea (shortness of breath), and gastrointestinal issues such as nausea and vomiting. These are generally classified as common (occurring in 1% to 10% of patients) or very common ( 10% ).

Serious Safety Restrictions

Biosotal is contraindicated in patients with pre-existing conditions that increase risk, including:

  • Severe bradycardia (heart rate less than 50 bpm).
  • Second or third-degree atrioventricular (AV) block, or sick sinus syndrome (unless a functioning pacemaker is present).
  • Congenital or acquired long QT syndromes, or a baseline QTc interval >450 ms.
  • Uncontrolled congestive heart failure, cardiogenic shock, and bronchial asthma/related bronchospastic conditions.
  • Severe renal impairment (creatinine clearance <40 mL/min) or uncorrected hypokalemia/hypomagnesemia.

Abrupt withdrawal of the medication is restricted, particularly in patients with coronary artery disease, due to the risk of exacerbating angina or precipitating myocardial infarction.

Overdose and Emergency Response

Overdosage with Sotalol (Biosotal) is a potentially life-threatening event explicitly described in regulatory labeling due to the risk of severe cardiac instability.

Documented Overdose Manifestations

Domain Official Regulatory Statements
Documented presentations Overdosage may manifest as excessive bradycardia (slow heart rate), severe hypotension (low blood pressure), dizziness, fatigue, or syncope (fainting) [Source 1.1].
Life-threatening outcomes The primary severe risk is Torsade de Pointes (a type of ventricular tachycardia) resulting from excessive QT interval prolongation, which can progress to cardiac asystole [Source 2.6].

Required Emergency Actions

Official documents mandate specific actions be taken when an overdose is suspected:

  • Immediate Medical Help: Contact the poison control helpline or call emergency services immediately if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened [Source 1.1].
  • Supportive Management: The treatment is symptomatic and supportive, and no specific antidote is known [Implied by treatment focus].
  • Interventions: Regulator-described interventions for severe effects include the use of Atropine for bradycardia, Magnesium sulfate for Torsade de Pointes, and transvenous cardiac pacing [Source 2.2]. Hemodialysis is listed as a means to help clear the drug from the body [Source 2.4].

Population-Specific Notes

Patients with renal impairment are at increased risk of high Sotalol concentrations, which heightens the potential for the life-threatening arrhythmia, Torsade de Pointes [Source 2.6]. Continuous electrocardiographic monitoring is required in the overdose setting due to the risk of malignant arrhythmias [Source 2.2].

Therapeutic Uses of Biosotal

Main Uses of Biosotal

Biosotal is a medication classified as an antiarrhythmic agent. It is primarily used to manage and treat specific types of irregular heart rhythms, also known as arrhythmias. By acting on the electrical signals within the heart muscle, it helps to maintain a stable and predictable heartbeat.

Treatment of Ventricular Arrhythmias

The primary indication for Biosotal is the management of life-threatening ventricular arrhythmias. These are heart rhythm disturbances that originate in the lower chambers of the heart (the ventricles). The medication is used to suppress documented cases of sustained ventricular tachycardia, a condition where the heart beats too rapidly, which can interfere with effective blood circulation.

Maintenance of Normal Sinus Rhythm

Biosotal is also utilized for patients with atrial fibrillation or atrial flutter. In these cases, the medication is employed to maintain normal sinus rhythm—the heart's natural, regular beating pattern—after the patient has been converted from an irregular rhythm. It helps to prolong the time between episodes of arrhythmia, thereby stabilizing heart function over a longer period.

Benefits of Treatment

Heart Rhythm Stabilization

The central benefit of Biosotal is its ability to regulate the heart's electrical activity. By slowing the nerve impulses and electrical conduction in the heart, it prevents the rapid or irregular firing that leads to arrhythmias.

Improved Cardiac Efficiency

When the heart maintains a regular rhythm, it can pump blood more effectively throughout the body. Stabilizing the heartbeat helps ensure that the heart chambers have enough time to fill and contract properly, which supports overall cardiovascular stability and reduces the physical strain caused by chronic irregular rhythms.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Biosotal — official regulatory information

Eligibility scope

Classification Populations/Conditions (Regulatory Statement)
Populations for whom use is contraindicated Sinus bradycardia (heart rate lt 50 bpm), Sick sinus syndrome, Second or third-degree AV block (unless a functional pacemaker is present), Congenital or acquired Long QT syndrome (QT interval gt 450 ms), Cardiogenic shock or decompensated heart failure, Serum potassium lt 4 mEq/L, Bronchial asthma or related bronchospastic conditions, Severe renal impairment (creatinine clearance lt 40 mL/min), Hypersensitivity to sotalol.
Populations for whom use is restricted Renal impairment (dose reduction required for creatinine clearance lt 60 mL/min), History of congestive heart failure (use with caution, start with lowest dose), Unstable diabetes (may mask hypoglycemia symptoms), Hyperthyroidism (may mask symptoms), Elderly patients (start with low dose and closely monitor).
Age-related eligibility rules Children and adolescents: Safety and efficacy have not been established. Use is generally avoided.
Pregnancy and lactation Lactation is contraindicated; sotalol is excreted into breast milk. Use in pregnancy is typically avoided; close fetal monitoring is necessary if administered.

Eligibility classifications (high-level)

Regulatory documents define strict exclusions for Biosotal use, primarily due to the risk of life-threatening proarrhythmia associated with QT interval prolongation. This risk necessitates the drug's reservation for highly symptomatic or life-threatening conditions, requiring initial hospitalization and continuous ECG monitoring. Eligibility is also heavily constrained by pre-existing cardiac conditions, respiratory diseases, and the patient’s kidney function.

What should I know about interactions with other medicines?

The official interaction profile for Sotalol hydrochloride (Biosotal) is explicitly defined by its dual antiarrhythmic action and its reliance on renal clearance. The regulatory documentation mandates strict controls on co-administration due to the inherent risk of additive effects.

  • The use of other Class I or Class III antiarrhythmics or any medicine known to prolong the QTc interval is formally avoided or restricted due to the significant risk of cumulative proarrhythmia.
  • The intravenous administration of Verapamil or Diltiazem is strictly contraindicated due to additive depressant effects on atrioventricular conduction and ventricular function.
  • Co-administration with aluminum- or magnesium-based antacids results in a formal reduction of Sotalol's absorption. To mitigate this effect, official labels require that Sotalol and these antacids be administered at least two hours apart. Simultaneous ingestion of milk or dairy products can also officially decrease the drug’s absorption.
  • Concomitant use with other beta-blocking agents or catecholamine-depleting agents may lead to enhanced bradycardia or hypotension. For patients receiving Insulin or Oral Antidiabetics, beta-blockade may officially mask the symptom of tachycardia associated with hypoglycemia.
  • Sotalol’s concentration and associated interaction risks are heightened in cases of renal impairment due to its decreased clearance. Electrolyte disturbances such as hypokalemia or hypomagnesemia must be corrected, as they officially augment the drug’s QT prolongation effect.

Mechanism of Action

Dual-Action Electrical and Autonomic Stabilization

The antiarrhythmic function of Sotalol is defined by its combined Class II (boldsymbolbeta-blocker) and Class III (boldsymbolIKr channel blocker) effects. This single compound concurrently reduces input from the sympathetic nervous system while electrically modulating the heart muscle, resulting in a dual-action influence on cardiac electrical and autonomic function.


Electrical Modulation via Potassium Channel Blockade

The primary mechanism involves the blockade of the rapid delayed-rectifier potassium current (boldsymbolIKr), which governs the heart cell's electrical recovery. By inhibiting the flow of potassium ions ( K^+) out of the cell, the drug extends the time the heart muscle remains electrically unexcitable. This targeted inhibition prolongs the action potential duration ( APD), which establishes a prolonged effective refractory period ( ERP), and physiologically resists the re-entry of electrical impulses.


Autonomic Dampening and Conduction Modulation

The complementary action is the non-selective antagonism of boldsymbolbeta1- and boldsymbolbeta2-adrenergic receptors. This mechanism blocks the activation signals from catecholamines, which decreases SA node automaticity and reduces conduction velocity through the AV node. This reduction in sympathetic signaling produces a reduction in firing rate (negative chronotropy), which, in turn, enhances the electrical Class III mechanism due to its reverse use-dependence property.

Dosage and Administration Information

How Biosotal is Used: Official Administration Guidelines

Biosotal (Sotalol) is administered through specific official protocols to ensure consistent and proper use. The medicine is available as oral tablets and as an intravenous (IV) solution, dictating its two approved routes of administration.

Standard Dosing and Administration

Therapy must be initiated or re-initiated in a facility capable of continuous ECG monitoring and cardiac resuscitation for a minimum of three days or until steady-state is achieved on the maintenance dose.

Adult Regimens

Administration Detail Official Requirement
Starting Dose Typically 80 mg twice daily (BID).
Maintenance Range Usually 160 mg to 320 mg total daily dose, divided BID.
Titration Interval Dose increments (e.g., 80 mg/day) must occur no sooner than every 3 days.
Timing (Oral) Preferably taken 1–2 hours before meals to avoid reduced absorption.
IV Infusion Rate Administered as a diluted infusion over 5 hours using a volumetric pump.

Population-Specific Adjustments

Dosage interval is strictly dependent on renal function, which governs the drug’s elimination rate:

  • Kidney Impairment: The dosing interval must be adjusted based on the estimated Creatinine Clearance (CrCl). For instance, a CrCl between 30–59 mL/min necessitates administration every 24 hours, instead of the standard 12 hours.
  • Liver Impairment: No specific dosage adjustment is required for patients with hepatic impairment.

Discontinuation and Handling

The medicine is used for long-term management. If chronic therapy is stopped, the dosage should be gradually reduced over a period of one to two weeks, as directed by official guidance. The IV solution requires mandatory dilution before infusion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Biosotal

Evidence for use in Life-Threatening Ventricular Arrhythmias

This section summarizes the findings from clinical trials and long-term observational data that evaluated outcomes related to sustained ventricular arrhythmias and assessed all-cause mortality as an endpoint in studied populations.

The primary research for this indication examined specific cohorts of adult patients with documented, severe ventricular rhythm problems, such as sustained ventricular tachycardia. Studies reported measurements related to the frequency of these specific ventricular arrhythmias in the observed populations. What remains uncertain is the long-term impact on patient survival. Specific trials were not designed to evaluate the enhanced survival outcome for patients with life-threatening ventricular arrhythmias. This research describes an area where long-term outcomes are not extensively characterized, which is a key research limitation.

Evidence for use in Atrial Fibrillation and Atrial Flutter

This part outlines the structure and results of Randomized Controlled Trials (RCTs) and comparative studies designed to measure outcomes related to delaying the recurrence of symptomatic Atrial Fibrillation or Atrial Flutter (AFib/AFL).

Research in this area explored the maintenance of a stable rhythm after the heart was returned to normal sinus rhythm. RCTs reported measurements showing patterns related to the time elapsed before the recurrence of AFib or AFL when compared to control groups. Comparative evidence against certain newer antiarrhythmic therapies is lacking. Additionally, research describes variability in administration and monitoring protocols, particularly concerning the necessary in-hospital initiation and observation period required before transitioning to out-of-hospital use.

Studies on Long-Term Outcomes and Durability

Research examined long-term durability by observing responses over defined time intervals, tracking patients for periods up to one year and, in some observational cohorts, longer. For the life-threatening ventricular arrhythmia indication, the key research limitation remains: there is limited information for long-term outcomes regarding the enhanced survival outcome.

What is Still Uncertain or Under Research

The research consistently highlights the risk for the development of new or worsening ventricular arrhythmias (proarrhythmia), which is a key factor observed in some studies and frequently evaluated in patients. Data for certain groups remain insufficient, and the certainty remains low in areas where robust, long-term RCTs have not been feasible.

Key Studies & References

  1. Sotalol Hydrochloride Tablets, USP (Product Label) - Dailymed
  2. Mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: a randomised, double-blind trial of the effect of adding d,l sotalol to conventional treatment (SWORD)

Frequently Asked Questions (FAQ)

Common questions about Biosotal (FAQ)


Q: How long does it typically take to feel the effects of Biosotal?

According to official product information, the medicine typically reaches its peak concentration in the bloodstream approximately 2.5 to 4 hours after taking an oral dose. However, the body needs time to reach a steady-state concentration—where the level of the drug in your system remains consistent—which usually occurs after 2 to 3 days of regular administration.


Q: Can I drink alcohol while taking Biosotal?

Regulatory information indicates that alcohol may have an additive effect when combined with Biosotal, potentially causing symptoms like dizziness, lightheadedness, or fainting due to further reduction in blood pressure. Monitoring for these possible enhanced effects is relevant when consuming alcohol while on this medication.


Q: Can pregnant women use Biosotal?

Official regulatory documents, such as the FDA’s classification system, indicate that animal studies have not shown a risk to the developing fetus, though other classifications note that the drug's known effects could potentially be harmful. Generally, use during pregnancy is avoided unless the potential benefits are determined to outweigh the potential risks. When the medication is administered during pregnancy, close fetal monitoring is a procedure that may be utilized, according to regulatory information.


Q: Is it necessary to have regular blood tests while on Biosotal?

Official guidance indicates that monitoring of kidney function and electrolyte levels, such as potassium and magnesium, is relevant to manage safety risks associated with the medicine. These monitoring steps are important because changes in these levels can heighten the risk of serious side effects and may necessitate dose adjustments.


Q: Can people with kidney problems take Biosotal?

Because this medicine is eliminated primarily by the kidneys, use is contraindicated in patients with severe kidney impairment (typically defined as creatinine clearance less than 40 mL/min). For those with moderate kidney impairment, the drug can be used, but the administration interval must be formally adjusted based on the degree of kidney function to prevent drug accumulation in the body.


Q: Can Biosotal affect my ability to drive?

Official documentation advises caution when performing tasks that require full alertness, such as driving or operating heavy machinery. This caution is based on the possibility of side effects such as tiredness, dizziness, or lightheadedness, which can impact concentration and reaction time until an individual knows how the medicine affects them.


Q: Can Biosotal make existing depression worse?

The official adverse reaction lists for this medicine include reports of central nervous system effects such as anxiety, confusion, mood changes, and depression. Reports of such effects highlight the relevance of discussing any history of depression or changes in mood with a healthcare professional.


Q: Is there a generic version of Biosotal available?

Yes, the active ingredient in Biosotal, Sotalol hydrochloride, is available in the form of a generic drug. Regulatory agencies have approved these generic versions, meaning they are chemically and therapeutically equivalent to the brand-name product.


Q: How long does Biosotal stay in the body after the last dose?

The medicine's elimination half-life is approximately 12 hours. This means it takes about 12 hours for the concentration of the drug in the plasma to be reduced by half. The drug is largely cleared from the body through the kidneys without being chemically changed.


Q: Is Biosotal used for controlling irregular heartbeats in children?

Official regulatory guidance states that the safety and effectiveness of this medication in children have not been fully established. Therefore, its use in pediatric patients is generally avoided or reserved for specific, specialist-monitored conditions.


Q: Are the side effects of Biosotal permanent?

Official patient information often notes that common side effects like tiredness or headache may be temporary and can improve or become less noticeable as the body adjusts to the medication, usually during the initial weeks of use. However, any serious or persistent side effects may require the medication to be stopped, as directed by a healthcare professional.


Q: Does Biosotal cause changes in weight?

Weight changes are not listed among the common side effects in the official labeling. However, weight gain has been reported in association with symptoms of heart failure, which is a serious condition that requires management and monitoring.


Q: Can I take multivitamins or supplements while using Biosotal?

Official information indicates that minerals often found in multivitamins or supplements, such as magnesium or aluminum, may reduce the body's absorption of Biosotal. To minimize any potential effect on how much medicine is absorbed, separation of administration times by at least two hours is a required measure when using certain antacids and is relevant when taking supplements containing these minerals.


Q: Is Biosotal a drug that is used for emergency situations?

The medicine is available as an intravenous solution, which allows for rapid administration when needed. However, the primary use outlined in official indications is for the management and prevention of specific types of abnormal heart rhythms, which requires careful monitoring.


Q: Can Biosotal cause strange dreams or sleep disturbances?

Yes, official lists of adverse reactions include reports of sleep disturbances, including insomnia, and unusual or strange dreams. These are classified as effects that impact the central nervous system.


Q: Does Biosotal affect fertility?

Official regulatory documents and research studies on reproductive toxicity have found no reports suggesting that the use of Biosotal affects or reduces fertility in either male or female patients.


Q: Is it possible to be allergic to Biosotal?

Yes. Hypersensitivity (a severe allergic reaction) to Sotalol hydrochloride or any of the inactive ingredients is listed as an official contraindication, meaning anyone with a known allergy to the drug must not use it. Signs of a serious allergic reaction may require immediate medical attention.


Q: Can the side effects of Biosotal become less noticeable over time?

Patient information from official sources often notes that common side effects, such as headache or feeling tired, may be temporary. These symptoms can often improve or become less noticeable as the body adjusts to the medication, which typically occurs during the first few weeks of use.


Q: Why is my doctor concerned about my heart's QT interval when I take Biosotal?

The primary action of this drug is to extend the heart's electrical recovery time, which is measured as the QT interval on an ECG. Regulatory documents require monitoring because excessive prolongation of this interval is associated with a specific, life-threatening risk of a new heart rhythm problem called Torsade de Pointes. Continuous ECG monitoring is used to ensure the interval stays within established safety limits.

How should Biosotal be stored and disposed of?

The storage and disposal of Biosotal (Sotalol hydrochloride) are governed by specific regulatory requirements to ensure product stability and public safety.

Official Storage Conditions

Requirement Official Labeled Instruction
Temperature Store tablets at Controlled Room Temperature (15 C to 30 C / 59 F to 86 F). Avoid excessive heat or freezing.
Protection Keep in a tightly closed, light-resistant container and in a dry place.
Child Safety Must be kept out of the sight and reach of children; dispense with a child-resistant closure.

Handling and Disposal

To maintain its stability over its shelf life, the product must be protected from both high heat and freezing. For final disposal, unused or outdated medication should be discarded in accordance with local requirements for pharmaceutical waste, as determined in consultation with a healthcare professional. Sotalol is not listed on the U.S. FDA's mandatory flushing list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biosotal found in:

A-Z Index: